NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $0.07 0.00 (0.00%) As of 11/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Sangamo Therapeutics Stock (NASDAQ:SGMO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sangamo Therapeutics alerts:Sign Up Key Stats Today's Range$0.07▼$0.0750-Day Range$0.07▼$0.0752-Week Range$0.06▼$0.77VolumeN/AAverage Volume8.10 million shsMarket Capitalization$30.66 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingReduce Company Overview Sangamo Therapeutics is a biotechnology company developing genomic medicines for serious diseases. Its research focuses on modifying or regulating genes and using engineered cells to produce potential treatments. The company’s technology platform includes zinc finger proteins, including zinc finger nucleases (ZFNs), which are designed to target specific genetic sequences. Sangamo applies its technologies across gene therapy, cell therapy and gene regulation programs, with research spanning areas such as rare diseases and neurological disorders. Founded in 1995 and formerly known as Sangamo BioSciences, the company is headquartered in Brisbane, California. It also works with pharmaceutical and biotechnology partners to develop and advance potential therapies.AI Generated. May Contain Errors. Read More Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGMO Stock News HeadlinesSangamo Therapeutics, Inc. Launches Auction Process for Clinical-Stage St-503 Program for Chronic Neuropathic PainOctober 13, 2026 | marketscreener.comMSangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain ProgramOctober 13, 2026 | globenewswire.comPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)Sangamo Therapeutics Completes Fabry Gene Therapy Asset SaleSeptember 21, 2026 | tipranks.comSangamo Therapeutics Advances Bankruptcy Asset Sale ProcessJuly 20, 2026 | tipranks.comSangamo Therapeutics Inc SGMOJuly 7, 2026 | morningstar.comMSangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and AstellasJune 24, 2026 | markets.businessinsider.comSangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assetsJune 24, 2026 | seekingalpha.comSee More Headlines SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $0.42 at the beginning of the year. Since then, SGMO stock has decreased by 82.4% and is now trading at $0.0740. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings data on Thursday, November, 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.08. The biopharmaceutical company had revenue of $581 thousand for the quarter, compared to analysts' expectations of $34.40 million. Sangamo Therapeutics had a negative net margin of 310.81% and a negative trailing twelve-month return on equity of 2,662.06%. Read the conference call transcript. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Editas Medicine (EDIT), Micron Technology (MU), Bristol Myers Squibb (BMY), Alibaba Group (BABA) and Advanced Micro Devices (AMD). Company Calendar Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (18m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SGMO's financial health is in the Red zone, according to TradeSmith. SGMO has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees480Year Founded1995Price Target and Rating Average Price Target for Sangamo Therapeutics$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+13,413.5%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$122.93 million Net Margins-310.81% Pretax Margin-312.25% Return on Equity-2,662.06% Return on Assets-132.12% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual Sales$39.55 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-1.85Miscellaneous Outstanding Shares414,289,000Free Float397,291,000Market Cap$30.66 million OptionableOptionable Beta1.30 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SGMO) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.